Alvotech, Teva Pharmaceuticals and FDA
Alvotech and Teva Pharmaceuticals announce FDA accepts Biologics License Application for AVT06
Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech’s proposed biosimilar to Eylea (aflibercept) 2 mg.
The company will report earnings before the open on Jan. 29 Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings ...
Teva Pharmaceutical says it has reached an agreement in principle to settle thousands of lawsuits accusing it of fuelling the opioid crisis in the US for up to $4.25 billion, including already ...
Teva Pharmaceutical Industries reported a slightly larger than expected rise in fourth-quarter profit, helped by double-digit sales gains in a trio of its branded drugs to treat migraines ...
The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition ...
Axsome Therapeutics shares were up 14% in premarket trading after reaching a settlement with Teva Pharmaceuticals. Shares were trading around $120.01. The stock is up 8.3% over the last year.
Catalyst Pharmaceuticals, Inc. has reached a Settlement Agreement with Teva Pharmaceuticals regarding patent litigation over the generic version of FIRDAPSE® (amifampridine) 10 mg tablets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback